Unfortunately, the company bet wrong on generics and it has cost them. They don't have a deal for Keppra and are unlikely to be even pursuing one. Mainly because there is no one to pursue at this point. The original bet on generics seemed sensible but the FDA and market forces undermined them. That is why the company has specifically pointed out in its presentations that it has switched its focus to NDA's.
Should any of the remaining ANDA's get approved, it will most likely be a relatively small bonus for the company and shareholders. If, on the other hand, the company gets Rexista filed, finalizes the patent for PODDRAS and works an attractive partnership deal that supplies it with much needed cash, the stock should really pop. If it just gets the first two but does not secure a nice, cash laden partnership deal, the stock will crater as cash will have to come from a dilutive stock offering.
So, it is white knuckles time for investors. It may not be for management as they may know they have several options to choose from regarding a partnership. Whatever happens, we should know within a couple of months or so.
News 
Market Data 
Discover 
